AI in Healthcare and Digital Health Video Recap —December 2, 2025

Here’s your biweekly AI in Healthcare and Digital Health video brief covering advances in AI-driven health services, cognitive science insights, digital innovation pilots, and and industry trends shaping the future of healthcare.

🎯 Watch Our Video Summary Capturing AI in Healthcare and Digital Health News from the Last Two Weeks

Dive deeper

🗓️ Explore weekly details and sources

Week 17–23 November 2025
Week 24–30 November 2025

📚 Find your one-stop page for the full AI and Digital Health archive.

Transcript

Welcome to the latest edition of in AI in Healthcare and Digital Health update covering breakthroughs in the past two weeks. Brought to you by LucidQuest.

Silicon Valley’s fertility tech push is accelerating. Orchid Health and Herasight market embryo screening beyond chromosome checks, including whole-genome approaches and polygenic risk scoring for inherited disease. Herasight reports internal validations suggesting 20% to 44% risk reductions when selecting among five embryos, while noting tradeoffs and self-published methods. Embryo editing remains restricted in many countries, yet startups like Preventive and Manhattan Genomics have attracted high-profile backers. Experts caution that trait selection claims are limited and ethics and regulation are still catching up.

Princeton researchers report that the prefrontal cortex reuses modular “cognitive blocks,” enabling monkeys to switch among related visual tasks by recombining shared components. Published in Nature, the work supports a compositional mechanism for flexible learning and highlights gaps between brains and AI systems that often show catastrophic interference.

Greece is integrating Sword Health’s AI care management into the National Health Information Line 1566 to assist triage and care navigation for more than 10 million people. The Ministry of Health plans independent monitoring and an implementation study to maintain transparency and evaluate performance.

AI companies are hiring more neuroscientists to boost energy efficiency and interpretability. Semafor profiles a growing shift of academic talent into industry roles, driven by competitive ambition and public funding pressures, with applications spanning recommender systems and model design.

An opinion in TechRadar argues humanoid robots could follow a smartphone-like adoption curve. Early pilots include Agility’s Digit at a GXO-operated warehouse, Figure robots at BMW Spartanburg, and Apptronik’s Apollo with Mercedes-Benz. Costs have been declining, but runtime, safety, and workflow integration remain key challenges, with innovations like rapid battery swapping under development.

Teva launched the Rise open innovation platform to pilot solutions across seven challenges in R&D, manufacturing and supply chain, commercial, and medical affairs. Selected startups can test and scale within Teva’s global network as part of its Pivot to Growth strategy, with planned multi-year investment.

A meta-analysis summarized by Earth.com finds that in text-only comparisons across 15 studies, chatbot responses are often rated as more empathic than clinician messages, including a largest dataset with 2,164 interactions. Dermatology studies were exceptions. The review assesses perceived empathy rather than accuracy or outcomes, suggesting a hybrid workflow where clinicians review AI-polished messages.

Stay ahead in AI in Healthcare and Digital Health! Like, share, and subscribe for our updates. Visit www.lqventures.com or email us at info@lqventures.com for expert healthcare consulting. See you next time!

Why It matters

IVF screening and prospective editing raise near-term access questions and long-term ethics, with investor attention accelerating timelines [1].
Neuroscience insights into compositionality may guide AI systems used in diagnostics, triage, and ops tooling [2][4].
National-scale AI triage pilots test whether digital front doors can safely extend capacity without eroding trust [3].
Pharma open innovation programs can speed validation of AI in regulated manufacturing and clinical design [6].
Patient communication quality may improve with AI drafting, provided clinicians review for accuracy and context [7].

🗓️ Explore weekly details and sources

Week 17–23 November 2025
Week 24–30 November 2025

📚 Find your one-stop page for the full AI and Digital Health archive.

FAQ

What exactly are Orchid Health and Herasight offering in IVF?

Polygenic and genome-wide embryo screening to estimate genetic disease risk, with some firms marketing trait-related scores. Details and validation vary, and embryo editing remains restricted [1].

Did the Princeton study prove a clinical benefit?

No. It reports neural reuse patterns in primate prefrontal cortex supporting flexible behavior. It suggests mechanisms that could inspire AI and clinical thinking, but not patient outcomes [2].

How broad is Sword Health’s Greece deployment?

Integration targets the national 1566 line to support >10M citizens, with independent evaluation planned to monitor performance and trust. Specific KPIs are not stated [3].

What does Teva’s Rise program cover for startups?

Seven challenge areas, including human-predictive biologics testing, AI trial simulations, predictive maintenance, quality risk prediction, and tender optimization, with pilots and potential scale across Teva sites [6].

Are chatbots ready to replace clinicians in patient messaging?

The review speaks to perceived empathy in text, not accuracy or safety. A practical model is clinician-authored advice polished by AI, then clinician-approved before sending [7].

Entities / Keywords

Orchid Health; Herasight; Manhattan Genomics; Preventive; Princeton University; prefrontal cortex; compositionality; Sword Health; Greece Ministry of Health; Teva Pharmaceutical Industries; Teva Rise; Industry 4.0; clinical trial simulations; humanoid robots (Agility Robotics Digit, Figure, Apptronik Apollo); AI empathy meta-analysis.